Bassir SH, Chase I, Paster BJ, Gordon LB, Kleinman ME, Kieran MW, Kim DM, Sonis A
Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome. J Periodontol. 2018 06; 89(6):635-644.
Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome.
DuBose AJ, Lichtenstein ST, Petrash NM, Erdos MR, Gordon LB, Collins FS
Proceedings of the National Academy of Sciences of the United States of America
Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):4206-4211.
Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts.
Guardiani E, Zalewski C, Brewer C, Merideth M, Introne W, Smith AC, Gordon L, Gahl W, Kim HJ
Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. Laryngoscope. 2011 Oct; 121(10):2250-5.
Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome.
The cell nucleus and aging: tantalizing clues and hopeful promises. PLoS Biol. 2005 Nov; 3(11):e395.
The cell nucleus and aging: tantalizing clues and hopeful promises.
Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003 May 15; 423(6937):293-8.
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, Ratner D, Worman HJ, Gordon LB, Djabali K
Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS One. 2010 Jun 15; 5(6):e11132.
Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB
Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension. 2012 Jan; 59(1):92-7.
Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome.
Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K
Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open. 2012 Jun 15; 1(6):516-26.
Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo.
Gordon LB, Shappell H, Massaro J, D'Agostino RB, Brazier J, Campbell SE, Kleinman ME, Kieran MW
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 04 24; 319(16):1687-1695.
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2154-9.
Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, Hascall V, Toole BP
Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome. Hum Genet. 2003 Jul; 113(2):178-87.
Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome.
Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB
The journals of gerontology. Series A, Biological sciences and medical sciences
Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7.
Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome.
Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. J Gerontol A Biol Sci Med Sci. 2008 Aug; 63(8):777-87.
Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science.
Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO, Gahl WA, Introne WJ
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 07; 358(6):592-604.
Phenotype and course of Hutchinson-Gilford progeria syndrome.
Ullrich NJ, Silvera VM, Campbell SE, Gordon LB
AJNR. American journal of neuroradiology
Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8.
Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome.
Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW
A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol. 2012 Sep; 42(9):1089-98.
A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome.
Lessel D, Ozel AB, Campbell SE, Saadi A, Arlt MF, McSweeney KM, Plaiasu V, Szakszon K, Szollos A, Rusu C, Rojas AJ, Lopez-Valdez J, Thiele H, Nürnberg P, Nickerson DA, Bamshad MJ, Li JZ, Kubisch C, Glover TW, Gordon LB
Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations. Hum Genet. 2018 Dec; 137(11-12):921-939.
Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations.
The Progeria Research Foundation 9th International Scientific Workshop Many Pathways, One Goal
Associate Professor of Anaesthesia (Pediatrics)
Associate Professor of Orthopedic Surgery
Julia Dyckman Andrus Professor of Surgery
Progerin as a Biomarker for Hutchinson-Gilford Progeria Syndrome
Tsai A, Johnston PR, Gordon LB, Walters M, Kleinman M, Laor T
Skeletal maturation and long-bone growth patterns of patients with progeria: a retrospective study. Lancet Child Adolesc Health. 2020 04; 4(4):281-289.
Skeletal maturation and long-bone growth patterns of patients with progeria: a retrospective study.
Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Xiong ZM, Tavarez UL, Davison LM, Gete YG, Mao X, Newby GA, Doherty SP, Narisu N, Sheng Q, Krilow C, Lin CY, Gordon LB, Cao K, Collins FS, Brown JD, Liu DR
In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021 01; 589(7843):608-614.
In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
The Progeria Research Foundation 10th International Scientific Workshop, Researching Possibilities, ExTENding Lives
Erdos MR, Cabral WA, Tavarez UL, Cao K, Gvozdenovic-Jeremic J, Narisu N, Zerfas PM, Crumley S, Boku Y, Hanson G, Mourich DV, Kole R, Eckhaus MA, Gordon LB, Collins FS
A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 03; 27(3):536-545.
A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.
Puttaraju M, Jackson M, Klein S, Shilo A, Bennett CF, Gordon L, Rigo F, Misteli T
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 03; 27(3):526-535.
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.
Gordon LB, Tuminelli K, Andrés V, Campisi J, Kieran MW, Doucette L, Gordon AS
The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives - webinar version scientific summary. Aging (Albany NY). 2021 03 17; 13(6):9143-9151.
The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives - webinar version scientific summary.
Author Correction: Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 Jul; 27(7):1309.
Author Correction: Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.
Koblan LW, Erdos MR, Gordon LB, Collins FS, Brown JD, Liu DR
Base editor treats progeria in mice. Nature. 2021 Jun 18.
Lessel D, Rading K, Campbell SE, Thiele H, Altmüller J, Gordon LB, Kubisch C
American journal of medical genetics. Part A
A novel homozygous synonymous variant further expands the phenotypic spectrum of POLR3A-related pathologies. Am J Med Genet A. 2022 01; 188(1):216-223.
A novel homozygous synonymous variant further expands the phenotypic spectrum of POLR3A-related pathologies.
Díez-Díez M, Amorós-Pérez M, de la Barrera J, Vázquez E, Quintas A, Pascual-Figal DA, Dopazo A, Sánchez-Cabo F, Kleinman ME, Gordon LB, Fuster V, Andrés V, Fuster JJ
Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome. Geroscience. 2023 04; 45(2):1231-1236.
Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome.
LeClair J, Massaro J, Sverdlov O, Gordon L, Tripodis Y
Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization. Stat Med. 2022 12 30; 41(30):5810-5829.
Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization.
Malloy J, Berry E, Correia A, Fragala-Pinkham M, Coucci S, Riley S, Spratt J, Knight Pfaffinger J, Massaro J, Ehrbar R, D'Agostino R, Gurary EB, Gordon LB, Kleinman ME
Physical & occupational therapy in pediatrics
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria Syndrome. Phys Occup Ther Pediatr. 2023; 43(4):482-501.
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria Syndrome.
Gordon LB, Norris W, Hamren S, Goodson R, LeClair J, Massaro J, Lyass A, D'Agostino RB, Tuminelli K, Kieran MW, Kleinman ME
Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Circulation. 2023 06 06; 147(23):1734-1744.
Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
Murtada SI, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, Li DS, Braddock DT, Tellides G, Gordon LB, Humphrey JD
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome. Elife. 2023 03 17; 12.
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
Olsen FJ, Gordon LB, Smoot L, Kleinman ME, Gerhard-Herman M, Hegde SM, Mukundan S, Mahoney T, Massaro J, Ha S, Prakash A
Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study. Circulation. 2023 06 06; 147(23):1782-1784.
Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study.
Odinammadu KO, Shilagardi K, Tuminelli K, Judge DP, Gordon LB, Michaelis S
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B. Nucleus. 2023 12; 14(1):2288476.
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Wang J, Yu Q, Tang X, Gordon LB, Chen J, Jiang B, Huang G, Fu H, Qian J, Liu Z, Mao J
Epidemiological characteristics of patients with Hutchinson-Gilford progeria syndrome and progeroid laminopathies in China. Pediatr Res. 2024 Apr; 95(5):1356-1362.
Epidemiological characteristics of patients with Hutchinson-Gilford progeria syndrome and progeroid laminopathies in China.
Olsen FJ, Biering-Sørensen T, Lunze F, Hegde SM, Colan SD, Ehrbar R, Massaro J, Ferraro AM, Harrild DM, Kleinman ME, Gordon LB, Prakash A
Journal of the American Heart Association
Abnormal Myocardial Deformation Despite Normal Ejection Fraction in Hutchinson-Gilford Progeria Syndrome. J Am Heart Assoc. 2024 Feb 06; 13(3):e031470.
Abnormal Myocardial Deformation Despite Normal Ejection Fraction in Hutchinson-Gilford Progeria Syndrome.
Gordon LB, Basso S, Maestranzi J, Aikawa E, Clift CL, Cammardella AG, Danesi TH, Del Nido PJ, Edelman ER, Hamdy A, Hegde SM, Kleinman ME, Maschietto N, Mehra MR, Mukundan S, Musumeci F, Russo M, Rybicki FJ, Shah PB, Suarez WA, Tuminelli K, Zaleski K, Prakash A, Gerhard-Herman M
Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome. Front Cardiovasc Med. 2024; 11:1356010.
Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome.
Progeria: translational insights from cell biology. J Cell Biol. 2012 Oct 01; 199(1):9-13.
Progeria: translational insights from cell biology.
Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30.
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.
Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ
Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7.
Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome.
Olsen FJ, Biering-Sørensen T, Lunze FI, Hegde SM, Ehrbar R, Massaro J, Ferraro AM, Harrild DM, Kleinman ME, Gordon LB, Prakash A
Longitudinal Changes in Myocardial Deformation in Hutchinson-Gilford Progeria Syndrome. Circ Cardiovasc Imaging. 2025 Feb; 18(2):e017544.
Longitudinal Changes in Myocardial Deformation in Hutchinson-Gilford Progeria Syndrome.
Krüger P, Schroll M, Fenzl FQ, Hartinger R, Lederer EM, Görlach A, Gordon LB, Cavalcante P, Iacomino N, Rathkolb B, Pimentel JAA, Östereicher M, Spielmann N, Wolf CM, de Angelis MH, Djabali K
International journal of molecular sciences
Baricitinib and Lonafarnib Synergistically Target Progerin and Inflammation, Improving Lifespan and Health in Progeria Mice. Int J Mol Sci. 2025 May 19; 26(10).
Baricitinib and Lonafarnib Synergistically Target Progerin and Inflammation, Improving Lifespan and Health in Progeria Mice.
The Progeria Research Foundation 12th Annual International Scientific Workshop: Coming of Age - Progeria Research Reaching for the Cure
Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG
Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol. 2014 Mar-Apr; 31(2):196-202.
Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome.
Gordon LB, Rothman FG, López-Otín C, Misteli T
Progeria: a paradigm for translational medicine. Cell. 2014 Jan 30; 156(3):400-7.
Progeria: a paradigm for translational medicine.
Wallner B, Giesbrecht G, Pasquier M, Gordon L, Lechner R, Brugger H, Paal P, Darocha T, Zafren K
Resuscitation of an Unconscious Victim of Accidental Hypothermia in 1805. Wilderness Environ Med. 2021 Dec; 32(4):548-553.
Resuscitation of an Unconscious Victim of Accidental Hypothermia in 1805.
Lechner R, Brugger H, Cools E, Darocha T, Paal P, Pasquier M, Strapazzon G, Wallner B, Walpoth B, Zafren K, Gordon L
The American journal of emergency medicine
Studies of hypothermic cardiac arrest outcomes without core temperature measurements are deeply flawed. Am J Emerg Med. 2024 Nov; 85:243-244.
Studies of hypothermic cardiac arrest outcomes without core temperature measurements are deeply flawed.
Cools E, Swol J, Wanscher M, Brugger H, Pasquier M, McIntosh S, Musi M, Oshiro K, Gordon L, Walpoth B, Hoffman JRH, Follis F, Zafren K, Paal P, Giraud R, Podsiadlo P, Martucci G, Darocha T
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ELSO 2025 Narrative Guideline on the Use of ECMO for Accidental Hypothermia. ASAIO J. 2025 Nov 01; 71(11):865-874.
ELSO 2025 Narrative Guideline on the Use of ECMO for Accidental Hypothermia.
Gordon L, Paal P, Ellerton JA, Brugger H, Peek GJ, Zafren K
Delayed and intermittent CPR for severe accidental hypothermia. Resuscitation. 2015 May; 90:46-9.
Delayed and intermittent CPR for severe accidental hypothermia.
Paal P, Gordon L, Strapazzon G, Brodmann Maeder M, Putzer G, Walpoth B, Wanscher M, Brown D, Holzer M, Broessner G, Brugger H
Scandinavian journal of trauma, resuscitation and emergency medicine
Accidental hypothermia-an update : The content of this review is endorsed by the International Commission for Mountain Emergency Medicine (ICAR MEDCOM). Scand J Trauma Resusc Emerg Med. 2016 Sep 15; 24(1):111.
Accidental hypothermia-an update : The content of this review is endorsed by the International Commission for Mountain Emergency Medicine (ICAR MEDCOM).
Lechner R, Brugger H, Paal P, Hüfner K, Agazzi G, Butler F, Gordon L, Darocha T, Zafren K
Survival in a Collapsed Stable for 37 Days After Avalanche Burial in 1755. Wilderness Environ Med. 2023 03; 34(1):113-119.
Survival in a Collapsed Stable for 37 Days After Avalanche Burial in 1755.
Cools E, Brugger H, Darocha T, Gordon L, Pasquier M, Walpoth B, Zafren K, Peek G, Paal P
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
About Rewarming Young Children After Drowning-Associated Hypothermia and Out-of-Hospital Cardiac Arrest. Pediatr Crit Care Med. 2024 Mar 01; 25(3):e171-e172.
About Rewarming Young Children After Drowning-Associated Hypothermia and Out-of-Hospital Cardiac Arrest.
Kreienkamp RJ, Gordon LB, Ehrbar R, Pendleton A, Schiferl DJ, Lyass A, Kleinman ME, Snyder BD, Gordon CM
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Lonafarnib Clinical Trials Demonstrate Uncoupling of the Muscle-Bone Unit in Hutchinson-Gilford Progeria Syndrome. J Bone Miner Res. 2025 Dec 04.
Lonafarnib Clinical Trials Demonstrate Uncoupling of the Muscle-Bone Unit in Hutchinson-Gilford Progeria Syndrome.
Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 01; 130(1):27-34.
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Atherosclerosis in ancient humans, accelerated aging syndromes and normal aging: is lamin a protein a common link? Glob Heart. 2014 Jun; 9(2):211-8.
Atherosclerosis in ancient humans, accelerated aging syndromes and normal aging: is lamin a protein a common link?
Gabriel D, Roedl D, Gordon LB, Djabali K
Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. Aging Cell. 2015 Feb; 14(1):78-91.
Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64.
Gordon LB, Kleinman ME, Massaro J, D'Agostino RB, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25.
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Gordon LB, Kieran MW, Kleinman ME, Misteli T
The decision-making process and criteria in selecting candidate drugs for progeria clinical trials. EMBO Mol Med. 2016 07; 8(7):685-7.
The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.
PRF 10th Anniversary Workshop on Progeria - "From Bench to Bedside in a Decade"
The 2007 Progeria Research Foundation Workshop on Hutchinson Gilford Progeria
Creating a Medical and Research Database for HGPS
The Progeria Research Foundation International Progeria Workshop
The Progeria Research Foundation 8th International Scientific Workshop Across the Table, Around the Globe
PRF 11th Anniversary Workshop on Progeria - Hand in Hand: Basic and Clinica
Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, Gordon LB, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V
Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):E7250-E7259.
Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations.
Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. PLoS One. 2016; 11(12):e0168988.
Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.
Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB
A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. J Med Genet. 2017 03; 54(3):212-216.
A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome.
New approaches to progeria. Pediatrics. 2007 Oct; 120(4):834-41.
Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ
Journal of immunology (Baltimore, Md. : 1950)
Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol. 1997 Sep 01; 159(5):2399-408.
Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
Gordon LB, Nolan SC, Ksander BR, Knopf PM, Harling-Berg CJ
Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. J Neuroimmunol. 1998 Aug 01; 88(1-2):77-84.
Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation.
Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, Collins FS
Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3250-5.
Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome.
Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, Gordon LB
Arteriosclerosis, thrombosis, and vascular biology
Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2301-9.
Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.
Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2005 Sep 06; 102(36):12879-84.
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Lemire JM, Patis C, Gordon LB, Sandy JD, Toole BP, Weiss AS
Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. Mech Ageing Dev. 2006 Aug; 127(8):660-9.
Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts.
McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, Djabali K
The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One. 2007 Dec 05; 2(12):e1269.
The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin.
Gordon LB, Harten IA, Patti ME, Lichtenstein AH
Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J Pediatr. 2005 Mar; 146(3):336-41.
Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome.
Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71.
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics. 2007 Oct; 120(4):824-33.
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development.
Mantagos IS, Kleinman ME, Kieran MW, Gordon LB
Ophthalmologic Features of Progeria. Am J Ophthalmol. 2017 Oct; 182:126-132.
Gabriel D, Shafry DD, Gordon LB, Djabali K
Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. Oncotarget. 2017 Sep 12; 8(39):64809-64826.
Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.
Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS
Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):8963-8.
Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome.
Greer MM, Kleinman ME, Gordon LB, Massaro J, D'Agostino RB, Baltrusaitis K, Kieran MW, Gordon CM
Journal of pediatric and adolescent gynecology
Pubertal Progression in Female Adolescents with Progeria. J Pediatr Adolesc Gynecol. 2018 Jun; 31(3):238-241.
Pubertal Progression in Female Adolescents with Progeria.
Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW
Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res. 2011 Jul; 26(7):1670-9.
Hutchinson-Gilford progeria is a skeletal dysplasia.
Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, Introne WJ, Gahl WA, Hart TC
Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009 Apr; 15(3):187-95.
Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes.
Gordon LB, Campbell SE, Massaro JM, D'Agostino RB, Kleinman ME, Kieran MW, Moses MA
Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res. 2018 05; 83(5):982-992.
Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008 Mar; 87(2):70-86.
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.
Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D'Agostino R, Kieran MW, Gerhard-Herman M, Smoot L
Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA Cardiol. 2018 04 01; 3(4):326-334.
Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome.
Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol. 1992 Sep; 40(1):81-7.
Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites.